A PdMo bimetallene with precise wavelength adjustment and catalysis for synergistic photothermal ablation and hydrogen therapy of cancer at different depths
by Baona Zhou, Jin Hou, Jinhai Si, Lei Bai, Ping Zhang, Tao Yi, Wenhui Yi, Xin Cheng, Xun Hou, Yanru Wang, Yilong Tian
Abstract:
By delivering the idea of green and safe hydrogen energy and novel photothermal therapy to the biomedical field, engineering of therapeutic nanomaterials for treatment of major diseases (such as cancer) holds great significance. In this work, a novel PdMo bimetallene was synthesized by a solvothermal reduction method, and it was explored and applied in the field of anti-tumor therapy for the first time. The absorption peak of the PdMo bimetallene can be precisely adjusted in the NIR biological window (700-1350 nm) only by changing the synthesis time. At the same time, it also shows strong light absorption and high photothermal conversion efficiency. Specifically, the photothermal conversion efficiencies at 808 nm, 980 nm and 1064 nm are 43.1%, 51.7% and 69.15%, respectively. Surprisingly, a PdMo bimetallene is an efficient catalyst, which can effectively promote hydrogen production from the hydrolysis of ammonia borane (AB) under acidic and photothermal conditions. Benefitting from these excellent properties, a multifunctional composite nano therapeutic agent (PdMo@AB@HA) was developed via layer-by-layer surface modification with AB and hyaluronic acid (HA). In this way, the synergistic PTT/hydrogen therapy of PdMo@AB@HA composite nanosheets in the NIR-I and NIR-II windows (808 nm, 980 nm, and 1064 nm) on mouse tumor xenografts of different depths was realized. Furthermore, the controlled release of hydrogen, targeted endocytosis, efficient eradication of tumors of different depths and high biosafety were systematically proved in vitro and in vivo. This work not only provides a novel and efficient theranostic nanoplatform for efficient cancer theranostics, but also provides a new strategy for the development of safe and efficient new anti-tumor therapies.
Read more:
https://doi.org/10.1039/d1tb01284c
Related Articles:
The poor penetration of nanocarriers within tumor dense extracellular matrices (ECM) greatly restricts the access of anticancer drugs to the deep tumor cells, resulting in low therapeutic efficacy. Moreover, the high toxicity of the traditional chemotherapeutics inevitably causes undesirable side…
Aims: Doxorubicin is a drug widely used in clinical cancer treatment, but severe cardiotoxicity limits its clinical application. Autophagy disorder is an important factor in the mechanism of doxorubicin-induced cardiac injury. As the smallest molecule in nature, hydrogen has various…
Background: Ocular melanoma is a rare kind of eye malignancy that threatens the patient’s eyesight. Radiotherapy and surgical removal are the most commonly used therapeutic modalities, and nanomedicine has lately entered this field. Brachytherapy using Ruthenium-106 (106 Ru) ophthalmic plaques…
Combination therapy is an emerging strategy to overcome multidrug resistance (MDR) in hepatocellular carcinoma (HCC) chemotherapy treatment. However, the passive diffusion in traditional delivery systems greatly retards the approach and penetration of drugs into hepatocellular carcinoma cells and thus hinders…
Near-infrared (NIR) laser-induced photoimmunotherapy has aroused great interest due to its intrinsic non-invasiveness and spatiotemporal precision, while immune evasion evoked by lactic acid (LA) accumulation severely limits its clinical outcomes. Although several metabolic interventions have been devoted to ameliorate immunosuppression,…
Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the world. Tumor removal remains the preferred frontline treatment; however, effective non-surgical interventions remain a high priority. 5-fluorouracil (5-FU) is a widely used chemotherapy agent, and molecular…






0 Comments